E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/6/2013 in the Prospect News PIPE Daily.

Alliqua takes in $1.1 million through private placement of its shares

Company also issues five-year warrants, each exercisable at $0.097

By Devika Patel

Knoxville, Tenn., June 6 - Alliqua, Inc. completed a $288,000 final tranche of a $1.1 million private placement of stock on May 31, according to an 8-K filed Thursday with the Securities and Exchange Commission. It raised another $576,000 on April 22 and $236,000 on April 11. Laidlaw & Co. (UK) Ltd. was the agent for the deal, which was slated to raise up to $3 million.

The company sold 2,913,580 common shares at $0.081 per share in the first tranche, 7,111,111 shares in the second tranche and 3,555,556 shares in the third tranche for a total of 13,580,247 shares. The price per share is a 1.25% premium to the April 10 closing share price of $0.08.

Investors also received warrants for 2,913,580 shares in the first tranche, warrants for 7,111,111 shares in the second tranche and warrants for 3,555,556 shares in the third tranche. Each warrant is exercisable at $0.097 for five years. The strike price is a 21.25% premium to the April 10 price.

The biomedical products company is based in New York.

Issuer:Alliqua, Inc.
Issue:Common stock
Amount:$1.1 million
Shares:13,580,247
Price:$0.081
Warrants:For 13,580,247 shares
Warrant expiration:Five years
Warrant strike price:$0.097
Agent:Laidlaw & Co. (UK) Ltd.
Settlement date:April 11 (for $236,000), April 22 (for $576,000), May 31 (for $288,000)
Stock symbol:OTCBB: ALQA
Stock price:$0.08 at close April 10
Market capitalization:$17.01 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.